There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Health Catalyst (HCAT – Research Report), Regeneron (REGN – Research Report) and Merck & Company (MRK – Research Report) with bullish sentiments.
Health Catalyst (HCAT)
Barclays analyst Stephanie Davis maintained a Buy rating on Health Catalyst yesterday and set a price target of $14.00. The company’s shares closed last Wednesday at $9.45.
According to TipRanks.com, Davis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Health Catalyst has an analyst consensus of Strong Buy, with a price target consensus of $13.25.
See today’s best-performing stocks on TipRanks >>
Regeneron (REGN)
In a report released yesterday, Carter Gould from Barclays maintained a Buy rating on Regeneron, with a price target of $1050.00. The company’s shares closed last Wednesday at $947.82, close to its 52-week high of $973.99.
According to TipRanks.com, Gould is a 5-star analyst with an average return of
Regeneron has an analyst consensus of Strong Buy, with a price target consensus of $1034.11, implying a 9.7% upside from current levels. In a report issued on February 2, Wells Fargo also maintained a Buy rating on the stock with a $1050.00 price target.
Merck & Company (MRK)
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Merck & Company yesterday and set a price target of $135.00. The company’s shares closed last Wednesday at $125.82, close to its 52-week high of $128.06.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Merck & Company is a Strong Buy with an average price target of $136.00, implying an 8.3% upside from current levels. In a report issued on February 9, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $138.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HCAT:
- Health Catalyst to Announce Fourth Quarter and Full Year 2023 Operating Results and Host Conference Call on Thursday, February 22, 2024
- Tesla downgraded, Coinbase upgraded: Wall Street’s top analyst calls
- Health Catalyst upgraded to Buy from Neutral at Guggenheim
- Health Catalyst price target raised to $17 from $12 at Piper Sandler
- ‘Profitability Is the Key’: Barclays Says These 3 Health Tech Stocks Are Poised for Growth
